Litigation Details for In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation (E.D.N.Y 2018)
✉ Email this page to a colleague
In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation (E.D.N.Y 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-01-31 |
| Court | District Court, E.D. New York | Date Terminated | 2023-08-01 |
| Cause | 15:2 Antitrust Litigation | Assigned To | Nina Gershon |
| Jury Demand | Plaintiff | Referred To | Lois Bloom |
| Patents | 8,008,006; 8,629,111; 8,633,162; 8,642,556; 8,648,048; 8,685,930; 9,000,002; 9,248,191 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Biologic Drugs cited in In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation (E.D.N.Y 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-08-28 | 134 | Amended Complaint | 2014 as U.S. Patent Nos. 8,629,111 (“the ’111 patent”), 8,633,162 (“the ’162 patent”), 8,642,556 (…of the follow-on patents that Allergan has claimed cover Restasis: No. 8,629,111 (issued Jan. 14, …Ding I patent. 43. The second patent, U.S. Patent No. 5,981,607 (“the ’607 patent” or “the…subject of U.S. Patent No. 4,839,342 to Kaswan (“the ’342 patent” or “the Kaswan patent”). The Kaswan…work in two patents, the first of which was U.S. Patent No. 5,474,979 (“the ’979 patent” or “the Ding | External link to document |
| 2019-02-11 | 245 | Amended Complaint | 6780 patents: U.S. Patent Nos. 8,629,111 (“the ’111 patent”), 8,633,162 (“the ’162 patent”), 8,642,556… six second wave patents which it claims cover Restasis: U.S. Patent No. 8,629,111 (issued January …Orange Book listing 8,629,111 (the ’111 patent) January 14, 2014 … original patent filings. However, for these secondary patent filings, the original patents may become… the PTO issued U.S. Patent No. 5,474,979 (“the Ding I patent”). This patent disclosed Allergan’s | External link to document |
| 2018-04-04 | 53 | Amended Complaint | early 2014 as U.S. Patent Nos. 8,629,111 (“the ’111 patent”), 8,633,162 (“the ’162 patent”), 8,642,556 (… six second-wave patents that it asserts cover Restasis: U.S. Patent No. 8,629,111 (issued Jan. 14, …Ding I patent. 94. The second patent, U.S. Patent No. 5,981,607 (“the ’607 patent” or “the…improvidently issued patents; patent holders cannot knowingly wield invalid patents to thwart competition…of U.S. Patent No. 4,839,342 issued to Renee Kaswan (“the ’342 patent” or “the Kaswan patent”). The | External link to document |
| 2021-04-13 | 676 | 35.7 50.8 43.2 31.9 16.6 8.8 6.4 3.9 0.8 The …of various patents, for example Ding et al U.S. Patent 5,474,979; Garst U.S. 20 Patent 6,254,860; …of various patents, for example Ding et al U.S. Patent 5,474,979; Garst U.S. 20 Patent 6,254,860; …Activity." All of these patents, patent applications, provisional patent applications, and/or …in U.S. Patent Application Serial No. 11/897,177 (currently pending) regarding U.S. Patent No. 5,474,979 | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
